Identification of targetable FGFR gene fusions in diverse cancers.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Cancer Discovery

• Publication date

  2013-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/2159-8290.CD-13-0050PMID 23558953PMCID PMC3694764
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma.

  2013cited by this paper
• Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma

  2012cited by this paper
• Molecular Pathways Molecular Pathways : Fibroblast Growth Factor Signaling : A New Therapeutic Opportunity in Cancer

  2012cited by this paper
• The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer

  2012cited by this paper
• Recurrent R-spondin fusions in colon cancer

  2012cited by this paper
• The transcriptional landscape and mutational profile of lung adenocarcinoma

  2012cited by this paper
• Anticancer molecules targeting fibroblast growth factor receptors.

  2012cited by this paper
• Oncogenic FGFR3 gene fusions in bladder cancer

  2012cited by this paper
• FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor.

  2012cited by this paper
• Use of whole-genome sequencing to diagnose a cryptic fusion oncogene.

  2011cited by this paper
• Targeting mutant fibroblast growth factor receptors in cancer.

  2011cited by this paper
• Fibroblast growth factors and their receptors in cancer.

  2011cited by this paper
• Cancer genomics: from discovery science to personalized medicine

  2011cited by this paper
• Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study

  2011cited by this paper
• Detection of somatic copy number alterations in cancer using targeted exome capture sequencing.

  2011cited by this paper
• SWI/SNF nucleosome remodellers and cancer

  2011cited by this paper
• Functionally Recurrent Rearrangements of the MAST Kinase and Notch Gene Families in Breast Cancer

  2011cited by this paper
• A human sterile alpha motif domain polymerizome

  2011cited by this paper
• 8p11 myeloproliferative syndrome: a review.

  2010cited by this paper
• Advances in understanding cancer genomes through second-generation sequencing

  2010cited by this paper
• Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo

  2010cited by this paper
• Aligning Short Sequencing Reads with Bowtie

  2010cited by this paper
• ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time.

  2010cited by this paper
• Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

  2010cited by this paper
• Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study.

  2010cited by this paper
• 1-tert-Butyl-3-[6-(3,5-dimethoxy-phenyl)-2-(4-diethylamino-butylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea (PD173074), a Selective Tyrosine Kinase Inhibitor of Fibroblast Growth Factor Receptor-3 (FGFR3), Inhibits Cell Proliferation of Bladder Cancer Carrying the FGFR3 Gene Mutation along with Up-Regu

  2010cited by this paper
• Fibroblast growth factor signalling: from development to cancer

  2010cited by this paper
• Aberrant Receptor Internalization and Enhanced FRS2-dependent Signaling Contribute to the Transforming Activity of the Fibroblast Growth Factor Receptor 2 IIIb C3 Isoform*

  2009cited by this paper
• Translation of the Philadelphia chromosome into therapy for CML.

  2008cited by this paper
• EML4-ALK fusion lung cancer: a rare acquired event.

  2008cited by this paper
• The SPFH domain-containing proteins: more than lipid raft markers.

  2007cited by this paper
• Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer

  2007cited by this paper
• Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer

  2007cited by this paper
• The dimerization mechanism of LIS1 and its implication for proteins containing the LisH motif.

  2006cited by this paper
• RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture.

  2006cited by this paper
• Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

  2006cited by this paper
• BAR Domains as Sensors of Membrane Curvature: The Amphiphysin BAR Structure

  2004cited by this paper
• Gene expression profiling predicts clinical outcome of prostate cancer.

  2004cited by this paper
• Fusion of ETV6 to fibroblast growth factor receptor 3 in peripheral T-cell lymphoma with a t(4;12)(p16;p13) chromosomal translocation.

  2001cited by this paper
• Crystal structure of a procaspase-7 zymogen: mechanisms of activation and substrate binding.

  2001cited by this paper
• Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain

  1998cited by this paper
• p160ROCK, a Rho‐associated coiled‐coil forming protein kinase, works downstream of Rho and induces focal adhesions

  1997cited by this paper
• Characterization of the promoter region and oligomerization domain of H4 (D10S170), a gene frequently rearranged with the ret proto-oncogene.

  1995cited by this paper
• A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining

  1973cited by this paper

• FGFR rearrangements: oncogenic drivers and therapeutic targets.

  2026cites this paper
• The multiple roles of the disordered protein CCDC6 in cancer development.

  2026cites this paper
• From chemotherapy to molecular targeted therapy in advanced biliary tract cancer

  2026cites this paper
• Recent research progress in structural optimization and cancer treatment of novel selective FGFR inhibitors (2020-2025).

  2026cites this paper
• Lysosome-localized IRTKS condensates promote mTORC1 activity leading to MASLD and HCC.

  2026cites this paper
• FGFR2-Rearranged Biliary Tract Cancer: Biology, Resistance Mechanisms, and Emerging Therapeutic Strategies

  2026cites this paper
• Mechanisms of Clinical Resistance to Selective FGFR2 Inhibition by Lirafugratinib.

  2026cites this paper
• Fibroblast growth factor receptor inhibitors in glioma: a narrative review of recent advances

  2026cites this paper
• Low-grade non-muscle-invasive bladder cancer: molecular landscape, treatment strategies and emerging therapies

  2025cites this paper
• Molecular Pathogenesis of Uterine Sarcomas: Mechanisms and Implications for Treatment.

  2025cites this paper
• Molecular mechanisms and genetic features of cholangiocarcinoma: implications for targeted therapeutic strategies

  2025cites this paper
• Diffuse glioma with FGFR3::TACC3 gene fusion and prominent calcification: A case report

  2025cites this paper
• Digestive cancers: mechanisms, therapeutics and management

  2025cites this paper
• SplitFusion enables ultrasensitive gene fusion detection and reveals fusion variant-associated tumor heterogeneity

  2025cites this paper
• Recent progress in emerging molecular targeted therapies for intrahepatic cholangiocarcinoma.

  2025cites this paper
• Human papillomavirus integration induces oncogenic host gene fusions in oropharyngeal cancers.

  2025cites this paper
• Synthesis and optimization of LHQ766: A highly selective FGFR2 inhibitor with improved pharmacokinetics.

  2025cites this paper
• Phase Ib Trial of Fulvestrant, Palbociclib and Erdafitinib, a pan-FGFR Tyrosine Kinase Inhibitor, in HR+/HER2- Metastatic Breast Cancer.

  2025cites this paper
• FGFR2 Fusions or Rearrangements in Young Intrahepatic and Perihilar Cholangiocarcinoma Patients: Key Genetic Insights From a Pan‐Asian Study

  2025cites this paper
• FGFR3-TACC3 fusion gene promotes glioblastoma malignant progression through the activation of STAT3 signaling pathway

  2025cites this paper
• Insulin receptor tyrosine kinase substrate in health and disease (Review)

  2025cites this paper
• A Narrative Review of Current Advances and Future Changes Regarding Bladder Cancer Treatment

  2025cites this paper
• Systemic Therapy for Advanced Biliary Tract Cancers in 2026: Current Standard of Care and Emerging Therapeutic Strategies

  2025cites this paper
• Breast Cancer Progression by the FGF/FGFR Axis: A Metabolic Perspective

  2025cites this paper
• Oncogenic gene fusions in cancer: from biology to therapy

  2025cites this paper
• Application of RNA sequencing in urologic malignancies: Advances and challenges.

  2025cites this paper
• Incorporating Molecular Data Into Treatment Decision Making in Gastroesophageal and Pancreaticobiliary Cancers: Timing and Strategies.

  2024cites this paper
• The landscape of cancer-associated transcript fusions in adult brain tumors: a longitudinal assessment in 140 patients with cerebral gliomas and brain metastases

  2024cites this paper
• Advances in Immunooncology and Precision Medicine in Cholangiocarcinoma

  2024cites this paper
• Advancements in First-Line Treatment of Metastatic Bladder Cancer: EV-302 and Checkmate-901 Insights and Future Directions

  2024cites this paper
• FGFR Alterations in Thyroid Carcinoma: A Novel Class of Primary Drivers with Significant Therapeutic Implications and Secondary Molecular Events Potentially Mediating Resistance in Thyroid Malignancy

  2024cites this paper
• Targeting FGFR for cancer therapy

  2024cites this paper
• Molecular Targeting of the Fibroblast Growth Factor Receptor Pathway across Various Cancers

  2024cites this paper
• Potential therapeutic targets of the JAK2/STAT3 signaling pathway in triple-negative breast cancer

  2024cites this paper
• Discovery of LHQ490 as a highly selective fibroblast growth factor receptor 2 (FGFR2) inhibitor.

  2024cites this paper
• Mechanistic insights and the clinical prospects of targeted therapies for glioblastoma: a comprehensive review

  2024influential citation
• Durvalumab Plus Gemcitabine and Cisplatin in Patients with Advanced Biliary Tract Cancer: An Exploratory Analysis of Real-World Data

  2024cites this paper
• FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions

  2024cites this paper
• FGFR inhibition blocks NF-ĸB-dependent glucose metabolism and confers metabolic vulnerabilities in cholangiocarcinoma

  2024cites this paper
• Skin Development and Disease: A Molecular Perspective

  2024cites this paper
• Multicentric reticulohistiocytosis with oral and laryngeal involvement in association with autoimmune/inflammatory syndrome induced by adjuvants (ASIA): expanding the spectrum of two uncommon entities.

  2024cites this paper
• FGFR3::TACC3 fusions in head and neck carcinomas: a study of nine cases highlighting phenotypic heterogeneity, frequent HPV association, and a morphologically distinct subset in favor of a putative entity

  2024cites this paper
• The Complexity and Significance of Fibroblast Growth Factor (FGF) Signaling for FGF-Targeted Cancer Therapies

  2024cites this paper
• Case report: a case of lung squamous cell carcinoma with a novel FGFR3-IER5L fusion mutation responding to anlotinib

  2024cites this paper
• Challenges and prospects in utilizing technologies for gene fusion analysis in cancer diagnostics

  2024cites this paper
• IMPDH2 dephosphorylation under FGFR signaling promotes S-phase progression and tumor growth.

  2024cites this paper
• Development of CAR-T Therapies and Personalized Vaccines for the Treatment of Cholangiocarcinoma: Current Progress, Mechanisms of Action, and Challenges.

  2024cites this paper
• Assessment of MYC Gene and WNT Pathway Alterations in Early-Onset Colorectal Cancer Among Hispanic/Latino Patients Using Integrated Multi-Omics Approaches

  2024cites this paper
• A Highly Sensitive XNA-Based RT-qPCR Assay for the Identification of ALK, RET, and ROS1 Fusions in Lung Cancer

  2024cites this paper
• Oncogenic alterations in advanced NSCLC: a molecular super-highway

  2024cites this paper
• Case report: High-grade serous tubo-ovarian carcinoma with FGFR2::IQCG fusion and insights into targetability

  2024cites this paper
• Mechanisms of endocrine resistance in hormone receptor-positive breast cancer

  2024cites this paper
• FGFR Inhibition in Urothelial Carcinoma.

  2024cites this paper
• FGFR2 fusions assessed by NGS, FISH, and immunohistochemistry in intrahepatic cholangiocarcinoma

  2024cites this paper
• New perspectives in biliary tract cancers

  2024cites this paper
• The roles of FGFR3 and c-MYC in urothelial bladder cancer

  2024cites this paper
• Multi-Omics Classification of Intrahepatic Cholangiocarcinoma: A Systematic Review and Meta-Analysis

  2024cites this paper
• Distinct phenotypic consequences of cholangiocarcinoma-associated FGFR2 alterations depend on biliary epithelial cell state

  2024cites this paper
• Carotenoids as modulators of the PI3K/Akt/mTOR pathway: innovative strategies in cancer therapy

  2024cites this paper
• Novel gene fusions in human oropharyngeal carcinoma.

  2024cites this paper
• Expert Consensus on the Diagnosis and Treatment of FGFR Gene-Altered Solid Tumors

  2024cites this paper
• RACTICAL GUIDELINES FOR MOLECULAR TESTING OF CHOLANGIOCARCINOMA IN CLINICAL PRACTICE: ITALIAN EXPERTS' POSITION PAPER.

  2024cites this paper
• Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer Types

  2023cites this paper
• Diffuse Gliomas with FGFR3-TACC3 Fusions: Oncogenic Mechanisms, Hallmarks, and Therapeutic Perspectives

  2023cites this paper
• Non-Small Cell Lung Carcinoma With Clear Cell Features and FGFR3::TACC3 Gene Rearrangement

  2023cites this paper
• Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma.

  2023cites this paper
• Bladder cancer course, four genetic high-risk variants, and histopathological findings

  2023cites this paper
• Molecular Detection of FGFR2 Rearrangements in Resected Intrahepatic Cholangiocarcinomas: FISH Could Be An Ideal Method in Patients with Histological Small Duct Subtype

  2023cites this paper
• The Hallmarks of Liver Fluke Related Cholangiocarcinoma: Insight into Drug Target Possibility.

  2023cites this paper
• Past, present, and future of FGFR inhibitors in cholangiocarcinoma: from biological mechanisms to clinical applications

  2023cites this paper
• Genomics driven precision oncology in advanced biliary tract cancer improves survival

  2023cites this paper
• Cilia and Cancer: From Molecular Genetics to Therapeutic Strategies

  2023cites this paper
• Resistance mechanism to fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma.

  2023cites this paper
• Specific recognition of an FGFR2 fusion by tumor infiltrating lymphocytes from a patient with metastatic cholangiocarcinoma

  2023cites this paper
• Molecular pathology for cholangiocarcinoma: a review of actionable genetic targets and their relevance to adjuvant & neoadjuvant therapy, staging, follow-up, and determination of minimal residual disease

  2023cites this paper
• Precision Medicine and Immunotherapy Have Arrived for Cholangiocarcinoma: An Overview of Recent Approvals and Ongoing Clinical Trials.

  2023cites this paper
• How we treat advanced biliary tract cancers in the second-line setting.

  2023cites this paper
• Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics

  2023cites this paper
• High expression of FGFR3 predicts a better prognosis for patients with non-small cell lung cancer in a Chinese population

  2023cites this paper
• Infigratinib for the Treatment of Metastatic or Locally Advanced Cholangiocarcinoma With Known FGFR2 Gene Fusions or Rearrangements

  2023cites this paper
• Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma

  2023cites this paper
• First proficiency testing for NGS‐based and combined NGS‐ and FISH‐based detection of FGFR2 fusions in intrahepatic cholangiocarcinoma

  2023cites this paper
• RNA-seq reveals novel mechanistic targets of Livin in bladder cancer

  2023cites this paper
• Role of FGFR3 in bladder cancer: Treatment landscape and future challenges.

  2023cites this paper
• FGFR2 testing in cholangiocarcinoma: translating molecular studies into clinical practice

  2023cites this paper
• Clinical characteristics and targeted therapy of different gene fusions in non-small cell lung cancer: a narrative review

  2023cites this paper
• Updates in the use of targeted therapies for the treatment of cholangiocarcinoma

  2023cites this paper
• Cholangiocarcinoma — novel biological insights and therapeutic strategies

  2023cites this paper
• RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations

  2023cites this paper
• A Robust FISH Assay to Detect FGFR2 Translocations in Intrahepatic Cholangiocarcinoma Patients

  2023influential citation
• Decoding Oncofusions: Unveiling Mechanisms, Clinical Impact, and Prospects for Personalized Cancer Therapies

  2023cites this paper
• Analysis of rare fusions in NSCLC: Genomic architecture and clinical implications.

  2023cites this paper
• Characterization of the folding and binding properties of the PTB domain of FRS2 with phosphorylated and unphosphorylated ligands.

  2023cites this paper
• Friend or foe? The elusive role of hepatic stellate cells in liver cancer

  2023cites this paper
• Molecular therapeutic targets for cholangiocarcinoma: Present challenges and future possibilities.

  2022cites this paper
• Fibroblast growth factor receptor signalling dysregulation and targeting in breast cancer

  2022cites this paper
• Evolving Paradigms in the Systemic Treatment of Advanced Gallbladder Cancer: Updates in Year 2022

  2022cites this paper
• FGFR2::TACC2 fusion as a novel KIT‐independent mechanism of targeted therapy failure in a multidrug‐resistant gastrointestinal stromal tumor

  2022cites this paper
• Roles of fusion genes in digestive system cancers: dawn for cancer precision therapy.

  2022cites this paper
• Fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma: current status, insight on resistance mechanisms and toxicity management

  2022cites this paper